Abstract: Solid-state lighting devices, and more particularly, wire grid polarization structure for current spreading and polarization control for light emitting diode (LED) package, and a method for making the same are disclosed. The wire grid polarization structure can be configured to both polarize light emitted by an LED chip of the LED package as well as spread current on a layer of the LED chip, resulting in more even light emission across the LED chip. The wire grid polarization structure can be formed on a top surface of the LED chip, and be electrically coupled to an electrode to spread the current across the top surface of the LED chip. In an embodiment, the wire grid polarization structure can include interdigitated fingers that are coupled to both an anode and an electrode.

Abstract: A multistage connector assembly for a lumen decontamination system is provided. The assembly includes a main body, a multistage body, a multistage barrier, a connector, and one or more biasing members. The assembly includes a multistage barrier movable in the fluid passageway between a fully closed position in which each stage of the multistage barrier is in a closed position to each independently block flow in the fluid passageway and a fully open position in which each stage is in an open position to allow flow within the fluid passageway. The connector is configured to engage the multistage barrier when coupled to the main body to sequentially open each stage of the multistage barrier to enable flow through the fluid passageway. The biasing member(s) are configured to urge each stage of the multistage barrier towards a closed position that blocks flow in the fluid passageway.

Abstract: Personalized cancer vaccines are created by predicting whether a first neoantigen or a second neoantigen of an individual cancer patient has a stronger binding affinity for a human leukocyte antigen (HLA) complex of the patient and creating a particle containing the neoantigen with the stronger predicted binding affinity. Such a predicting step includes artificial intelligence, statistical modeling, or a combination thereof. Such a particle is created by encapsulating the neoantigen with the stronger predicted binding affinity for the HLA complex of the patient in a material. Placing the antigen in a particular sized particle is referred to here as Size Exclusion Antigen Presentation Control, (SEAPAC) used in methods of treating the patient using such a personalized cancer vaccine.

Abstract: Extended-release microsphere formulations comprising lurasidone are provided. In one aspect. the microsphere formulations are characterized in that the lurasidone is released in vivo in humans over a period of about 30 days or about 60 days. Methods for making and using the formulations are also provided.

Abstract: Extended-release microsphere formulations comprising lurasidone are provided. In one aspect, the microsphere formulations are characterized in that the lurasidone is released in vivo in humans over a period of about 30 days. Methods for making and using the formulations are also provided.

Abstract: Systems and methods of flow testing different workpieces in an automated testing station are described. Each workpiece comprises a flow path from an inlet to an outlet and the automated testing station comprises first and second sealing heads for injecting gas into the inlets of workpieces and collecting gas from the outlets of workpieces. The method includes performing a flow test by moving the flow test heads toward the workpieces while at the same time priming a flow of gas from the first sealing heads to the second sealing heads, prior to engaging the workpiece.

Abstract: Systems and methods of flow testing different workpieces in an automated testing station are described. Each workpiece comprises a flow path from an inlet to an outlet and the automated testing station comprises first and second sealing heads for injecting gas into the inlets of workpieces and collecting gas from the outlets of workpieces. The method includes performing a flow test by moving the flow test heads toward the workpieces while at the same time priming a flow of gas from the first sealing heads to the second sealing heads, prior to engaging the workpiece.

Abstract: Extended-release microsphere formulations comprising lurasidone are provided. In one aspect, the microsphere formulations are characterized in that the lurasidone is released in vivo in humans over a period of about 30 days. Methods for making and using the formulations are also provided.

Abstract: A mast step for a kayak sailing rig is provided. The mast step supports a mast relative to a deck of the kayak at a desired angle to facilitate an optimum sail shape. The step also has a convex below a surface which contacts the deck, allowing the mast to be rotated forward or aft in use, and in particular allowing the mast to be rotated from an upright position to a flat position against the deck of the kayak.

Abstract: A mast step for a kayak sailing rig is provided. The mast step supports a mast relative to a deck of the kayak at a desired angle to facilitate an optimum sail shape. The step also has a convex below a surface which contacts the deck, allowing the mast to be rotated forward or aft in use, and in particular allowing the mast to be rotated from an upright position to a flat position against the deck of the kayak.